eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
1/2012
vol. 50
 
Share:
Share:
more
 
 
abstract:
Original paper

Effects of tocilizumab on symptoms and signs of rheumatoid arthritis in Slovak patients

Jozef Rovenský
,
Ivan Rybár
,
Jozef Lukáč
,
Dagmar Mičeková
,
Alexandra Letkovská
,
Daniel Žlnay
,
Martin Žlnay
,
Marian Kovalančík
,
Jozef Zvarka
,
Roman Stančík

Reumatologia 2012; 50, 1: 9–15
Online publish date: 2012/03/02
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Background: Tocilizumab is a humanized monoclonal antibody against the interleukin 6 receptor. Large placebo-controlled randomized studies analysing the effects of tocilizumab led to its approval for clinical use in the USA and Europe in combination with methotrexate or as monotherapy.

Aim of the study: The aim of this study was to analyse the dynamics of subjective symptoms and objective signs of disease activity in Slovak patients with moderate to severe rheumatoid arthritis treated with tocilizumab.

Material and methods: This open-label single-centre non-randomized interventional study involved 32 patients with moderate to severe rheumatoid arthritis (Table I). Tocilizumab was administered every 4 weeks in a dose of 8 mg/kg bodyweight. Patients were followed for a period of 24 weeks. Assessment included the visual analogue scale (VAS) of pain, the Health Assessment Questionnaire (HAQ), as well as the number of tender and swollen joints. Biochemical parameters of inflammation such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured during the study. The DAS28 score, a standardized measure of disease activity in rheumatoid arthritis, was calculated.

Results: Tocilizumab treatment reduced VAS and HAQ scores by 75% and 34%, respectively. The number of tender and swollen joints decreased, on average, from 26 to 4 and from 16 to less than 1 per patient, respectively. Inflammation markers were reduced by 80% (ESR) and by 83% (CRP). DAS28 score decreased on average by 63% after 24 weeks of treatment (Fig. 1). All observed parameters were significantly lower after just 4 weeks of treatment with tocilizumab, following a single dose (Table II, p < 0.001).

Discussion: Tocilizumab is an effective medication for patients with moderate to severe rheumatoid arthritis. Rapid effects were observed, both on subjective symptoms and objective parameters of disease activity. This is the first study conducted solely on Slovak patients with rheumatoid arthritis showing the effects of inhibition of the interleukin 6 receptor. Further studies should focus on tocilizumab usage in larger cohorts of patients with the potential to uncover the causes of treatment benefit variability.

Conclusions: This study showed that treatment of patients suffering from moderate to severe rheumatoid arthritis with tocilizumab results in a rapid and lasting reduction of both subjective symptoms and objective signs of inflammation.
keywords:

tocilizumab, interleukin 6, joint inflammation, DAS28



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe